| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Research and development | $7.3M-37.2% | $11.6M+26.7% | $9.2M+55.1% | $5.9M-10.2% | $6.6M |
| General and administrative | $4.7M+10.9% | $4.2M-10.6% | $4.7M+4.5% | $4.5M+4.7% | $4.3M |
| Total operating expenses | $12.0M-24.3% | $15.8M+14.0% | $13.9M+33.1% | $10.4M-4.3% | $10.9M |
| Net operating loss | -$12.0M+24.3% | -$15.8M-14.0% | -$13.9M-33.1% | -$10.4M+4.3% | -$10.9M |
| Change in fair value of warrant liability | $2.1M+869.0% | -$271K | — | — | — |
| Interest income | $14K-61.1% | $36K+9.1% | $33K+1000.0% | $3K-88.5% | $26K |
| Total other income | $2.1M+992.8% | -$235K-812.1% | $33K+1000.0% | $3K-88.5% | $26K |
| Net loss | -$9.9M+38.5% | -$16.1M-15.9% | -$13.9M-32.8% | -$10.4M+4.1% | -$10.9M |
| Net loss per share, basic | -$4120.00+87.7% | -$33630.00+11.8% | -$38120.00-2359.4% | -$1550.00+45.2% | -$2830.00 |
| Weighted average number of common shares outstanding, basic | 2.4M+402.3% | 478K+31.3% | 364K-94.6% | 6.7M+74.8% | 3.8M |
| Net loss per share, diluted | -$4120.00+87.7% | -$33630.00+11.8% | -$38120.00-2359.4% | -$1550.00+45.2% | -$2830.00 |
| Weighted average number of common shares outstanding, diluted | 2.4M+402.3% | 478K+31.3% | 364K-94.6% | 6.7M+74.8% | 3.8M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.